SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Clinical trials for SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Matched conditions: SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Old malaria drug may tame lupus skin flares
Disease control Recruiting nowThis study tests whether quinacrine, a medication originally used for malaria, can safely reduce skin rashes and sores in people with cutaneous lupus erythematosus (CLE). Participants receive either quinacrine or a placebo for 12 weeks, then all receive quinacrine for another 12 …
Matched conditions: SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE2 • Sponsor: Victoria Werth • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill could tame skin lupus flares
Disease control Recruiting nowThis study tests an oral medication called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18–75 with moderate-to-severe CLE will receive either the drug or a placebo for 16 weeks. The mai…
Matched conditions: SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Lupus drug continuation trial offers hope for disease control
Disease control Recruiting nowThis study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being…
Matched conditions: SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC